OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
U1HS3458

Universal Health Services Inc

Healthcare Facilities & ServicesVerified

Universal Health Services Inc maintains a debt-to-equity ratio of 0.7, indicating a relatively balanced capital structure with moderate leverage. The company’s liquidity position is characterized as medium, with a current ratio of 1.28, suggesting it can cover short-term obligations but with limited surplus. Free cash flow of $187 million supports operational flexibility, though capital expenditures of $449.9 million in the period reflect ongoing investment in infrastructure. Profitability metrics show a return on equity (ROE) of 4.46% and a return on assets (ROA) of 2.05%, both below the industry median for healthcare facilities and services. These figures suggest the company is underperforming in asset utilization and shareholder returns relative to peers. Operating income of $436.4 million and net income of $289.2 million indicate stable earnings, but margins remain compressed compared to industry benchmarks. The company’s revenue is concentrated in the U.S., with no material geographic diversification disclosed. Segment-wise, the business operates through two primary divisions: behavioral health and general acute care. Revenue concentration in these segments exposes the company to regulatory and reimbursement risks tied to U.S. healthcare policy. Looking ahead, revenue is projected to grow by 2.1% in the current fiscal year and 1.8% in the next, based on analyst estimates and historical trends. However, the growth trajectory is constrained by industry-wide margin pressures and regulatory headwinds. Risk factors include liquidity constraints, as net cash is negative after subtracting total debt, and potential dilution from future capital-raising activities. The company’s dilution risk is currently assessed as low, but the presence of $4.54 billion in long-term debt introduces credit risk. Recent filings and transcripts highlight ongoing challenges in managing labor costs and adapting to changes in healthcare reimbursement models. The company has also faced scrutiny over facility compliance and operational efficiency, which could impact future earnings.

30-day price · U1HS34-46.85 (-20.8%)
Low$177.89High$224.74Close$177.89As of2 Jun, 00:00 UTC
Profile
CompanyUniversal Health Services Inc
TickerU1HS34.SA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Universal Health Services Inc operates as a healthcare facilities and services provider, generating revenue primarily through inpatient and outpatient care services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Universal Health Services Inc maintains a debt-to-equity ratio of 0.7, indicating a relatively balanced capital structure with moderate leverage. The company’s liquidity position is characterized as medium, with a current ratio of 1.28, suggesting it can cover short-term obligations but with limited surplus. Free cash flow of $187 million supports operational flexibility, though capital expenditures of $449.9 million in the period reflect ongoing investment in infrastructure. Profitability metrics show a return on equity (ROE) of 4.46% and a return on assets (ROA) of 2.05%, both below the industry median for healthcare facilities and services. These figures suggest the company is underperforming in asset utilization and shareholder returns relative to peers. Operating income of $436.4 million and net income of $289.2 million indicate stable earnings, but margins remain compressed compared to industry benchmarks. The company’s revenue is concentrated in the U.S., with no material geographic diversification disclosed. Segment-wise, the business operates through two primary divisions: behavioral health and general acute care. Revenue concentration in these segments exposes the company to regulatory and reimbursement risks tied to U.S. healthcare policy. Looking ahead, revenue is projected to grow by 2.1% in the current fiscal year and 1.8% in the next, based on analyst estimates and historical trends. However, the growth trajectory is constrained by industry-wide margin pressures and regulatory headwinds. Risk factors include liquidity constraints, as net cash is negative after subtracting total debt, and potential dilution from future capital-raising activities. The company’s dilution risk is currently assessed as low, but the presence of $4.54 billion in long-term debt introduces credit risk. Recent filings and transcripts highlight ongoing challenges in managing labor costs and adapting to changes in healthcare reimbursement models. The company has also faced scrutiny over facility compliance and operational efficiency, which could impact future earnings.
Key takeaways
  • Universal Health Services Inc has a balanced capital structure but faces liquidity constraints due to high debt levels.
  • ROE and ROA are below industry medians, indicating underperformance in asset utilization and profitability.
  • Revenue is concentrated in the U.S. and within two core segments, exposing the company to regulatory and reimbursement risks.
  • Analysts project modest revenue growth, but margin pressures and capital expenditures may limit upside.
  • Liquidity risk is elevated, and the company’s net cash position is negative after accounting for long-term debt.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$3.91B
Gross profit
Operating income$436.4M
Net income$289.2M
R&D
SG&A
D&A
SBC
Operating cash flow$1.08B
CapEx-$449.9M
Free cash flow$187.0M
Total assets$14.07B
Total liabilities$7.59B
Total equity$6.49B
Cash & equivalents$128.8M
Long-term debt$4.54B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$12.64B$1.35B$991.6M$599.3M
FY-3$13.40B$1.00B$675.6M$446.4M
FY-2$14.28B$1.18B$717.8M$488.8M
FY-1$15.83B$1.68B$1.14B$750.8M
FY0$17.36B$1.99B$1.49B$1.06B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$13.09B$6.09B$115.3M
FY-3$13.49B$5.92B$102.8M
FY-2$13.97B$6.15B$119.4M
FY-1$14.47B$6.67B$126.0M
FY0$15.53B$7.28B$137.8M
PeriodOCFCapExFCFSBC
FY-4$883.7M-$855.7M$599.3M
FY-3$996.0M-$734.0M$446.4M
FY-2$1.27B-$743.1M$488.8M
FY-1$2.07B-$943.8M$750.8M
FY0$1.86B-$1.02B$1.06B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$3.91B$436.4M$289.2M$187.0M
FQ-6$3.96B$381.2M$258.7M$154.2M
FQ-5$4.11B$472.5M$332.4M$224.8M
FQ-4$4.10B$454.8M$316.7M$217.4M
FQ-3$4.28B$500.3M$353.2M$235.7M
FQ-2$4.50B$521.7M$373.0M$292.8M
FQ-1$4.49B$517.2M$445.9M$317.6M
FQ0$4.50B$502.9M$348.7M$284.0M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$14.07B$6.49B$128.8M
FQ-6$14.35B$6.61B$106.1M
FQ-5$14.47B$6.67B$126.0M
FQ-4$14.88B$6.79B$126.8M
FQ-3$14.99B$7.03B$137.6M
FQ-2$15.34B$7.17B$112.9M
FQ-1$15.53B$7.28B$137.8M
FQ0$15.68B$7.46B$119.0M
PeriodOCFCapExFCFSBC
FQ-7$1.08B-$449.9M$187.0M
FQ-6$1.41B-$697.9M$154.2M
FQ-5$2.07B-$943.8M$224.8M
FQ-4$360.0M-$239.0M$217.4M
FQ-3$909.0M-$505.0M$235.7M
FQ-2$1.29B-$733.9M$292.8M
FQ-1$1.86B-$1.02B$317.6M
FQ0$411.7M-$217.2M$284.0M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$6.49B
Net cash-$4.42B
Current ratio1.3
Debt/Equity0.7
ROA2.1%
ROE4.5%
Cash conversion3.7%
CapEx/Revenue-11.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricU1HS34Activity
Op margin11.2%5.6% medp25 -4.2% · p75 12.6%above median
Net margin7.4%2.8% medp25 -3.4% · p75 8.8%above median
Gross margin36.5% medp25 23.7% · p75 65.2%
CapEx / revenue-11.5%-4.9% medp25 -11.5% · p75 -2.0%below median
Debt / equity70.0%69.3% medp25 7.9% · p75 120.9%above median
Observations
IR observations
Mean price target226.75 USD
Median price target221.74 USD
High price target320.00 USD
Low price target190.00 USD
Mean recommendation2.57 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count6.00
Hold count12.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate23.45 USD
Last actual EPS21.74 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-04-30 02:14 UTC#c6ac76fd
Market quoteclose USD 210.00 · shares 0.22B diluted
no public URL
2026-04-30 02:14 UTC#99f5c21c
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 20:30 UTCJob: 8e782588